In vitro and phase I clinical studies have found the potential additive or synergistic antitumour effects between anti‐PD‐1 antibodies and VEGF/VEGFR‐2 inhibitors [23, 24], which prompted us to investigate whether Apatinib combined with ABT‐199 can exert a better therapeutic effect in DLBCL. This evidence concerns the gene KDR and diffuse large B-cell lymphoma.